MRK Merck & Co., Inc. Loading... : Bullish and Bearish Analyst Opinions
From MRNA earnings callsLoading chart...
Top Calls
Feed
12:00
Jul 31
Jul 31
Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches. — A late strain update capability could allow Moderna to offer a better-matched vaccine in a given season, potentially shifting market share from incumbent flu vaccine makers.
HIGH
12:00
May 01
May 01
The initiation of the INT Phase III in stage 1 lung cancer as a monotherapy is a significant expansion of the addressable market and a potentially pivotal trial. — Success could open a huge market segment where treatment is surgery and watchful waiting, and also support a monotherapy profile for INT.
HIGH
13:00
Feb 13
Feb 13
Merck is the co-developer and commercial partner for Moderna's lead individualized cancer therapy (INT). Management's confidence is reinforced by positive five-year data, implying progress toward a potential BLA submission by Merck.
HIGH
About MRK Analyst Coverage
Buzzberg tracks MRK (Merck & Co., Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Stéphane Bancel, Stephen Hogue, Stéphane Boncel.